Free Trial

Boothbay Fund Management LLC Reduces Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Amedisys logo with Medical background

Boothbay Fund Management LLC reduced its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 95.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,215 shares of the health services provider's stock after selling 46,330 shares during the period. Boothbay Fund Management LLC's holdings in Amedisys were worth $201,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. raised its holdings in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after acquiring an additional 124 shares during the period. HBW Advisory Services LLC acquired a new position in Amedisys in the fourth quarter worth $38,000. Versant Capital Management Inc boosted its position in Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after buying an additional 183 shares during the last quarter. Vestcor Inc bought a new stake in Amedisys during the 4th quarter worth about $73,000. Finally, Venturi Wealth Management LLC raised its position in shares of Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after acquiring an additional 779 shares during the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Trading Up 0.3 %

Shares of NASDAQ AMED traded up $0.24 during trading on Friday, reaching $95.44. The company had a trading volume of 81,650 shares, compared to its average volume of 414,221. The company's fifty day moving average price is $92.91 and its 200-day moving average price is $91.74. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The stock has a market cap of $3.13 billion, a P/E ratio of 37.87, a PEG ratio of 1.78 and a beta of 0.96. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million for the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business's revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.03 EPS. As a group, research analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Stephens restated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $100.75.

View Our Latest Stock Report on AMED

Amedisys Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Should You Invest $1,000 in Amedisys Right Now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines